Skip to main content

Table 4 Peak and trough concentration data and estimates of amikacin pharmacokinetic parameters

From: An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration

Patient profile

Dose

Dosage interval

Cpmax

Cpmin

t1/2

k

TBC

Vd

(mg)

(h)

(mg l-1)

(mg l-1)

(h)

(h-1)

(l h-1)

(l)

P1A

900

24

31.3

3

6.80

0.102

2.858

28.03

P1B

900

24

33.8

4

7.63

0.091

2.583

28.44

P1C

1100

24

35.7

6.2

9.10

0.076

2.579

33.89

Mean

    

7.84

0.090

2.674

30.12

P2A

300

19

7.6

1.8

8.66

0.080

3.096

38.69

P2B

1500

24

50.2

2.8

5.52

0.125

3.761

29.97

P2C

1500

24

48.5

5.4

7.42

0.093

2.987

31.98

P2D

1500

29

49.4

5

8.47

0.082

2.719

33.24

P2E

1500

32

55.9

6.1

9.70

0.071

2.062

28.85

P2F

1500

29

53.8

7

9.51

0.073

2.239

30.74

Mean

    

8.21

0.088

2.811

32.25

CVVHDF Stopped P2G

1500

53.5

68.3

16.1

25.18

0.028

0.668

24.26

P3A

1500

24

44.9

2.8

5.74

0.121

3.911

32.42

P3B

1500

24

42.4

1.9

5.13

0.135

4.923

36.46

P3C

1500

24

46.5

2.1

5.26

0.132

4.278

32.46

Mean

    

5.38

0.129

4.371

33.78

P4A

600

12

16.2

4

5.45

0.127

4.563

35.88

P4B

600

12

23.4

5

5.16

0.134

3.961

29.52

Mean

    

5.31

0.131

4.262

32.70

P5A

1500

24

48.2

2.1

5.09

0.136

4.099

30.08

P5B

1500

25

52.4

2.4

5.39

0.128

3.701

28.81

P5C

1500

28

54.4

2.5

5.29

0.131

3.649

27.84

P5D

1500

28

55.8

2.5

6.03

0.115

3.137

27.28

Mean

    

5.45

0.128

3.646

28.50

Overall mean*

    

6.74

0.109

3.39

31.4

Standard deviation

    

1.69

0.025

0.82

3.27

Median

    

5.88

0.118

3.39

30.4

  1. * Excluding profile P2G.
  2. Cpmax: maximum serum concentration Cpmin: minimum serum concentration.
  3. t1/2: half life. Vd: volume of distribution. TBC: Total body clearance. k: elimination rate constant.
  4. PX (1–5): patients 1–5. PXA-PXE: first (A) to fifth (E) dosing interval during which serum concentration data was collected for patient PX.